全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

血钙水平对发热伴血小板减少综合征患者的预后评估价值
Prognostic Value of Serum Calcium Levels in Severe Fever with Thrombocytopenia Syndrome

DOI: 10.12677/acm.2024.1451407, PP. 133-141

Keywords: 发热伴血小板减少综合征,血钙水平,预后
SFTS
, Serum Calcium Levels, Prognosis

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的:探讨血钙水平对发热伴血小板减少综合征(SFTS)患者预后的预测价值。方法:采用回顾性研究,收集于安徽医科大学第一附属医院住院治疗的181例SFTS患者的临床资料,根据临床结局分为死亡组(44例)和存活组(137例),对比分析两组患者的年龄及各项实验室检测指标。采用单因素及多因素COX回归分析不良结局的独立危险因素,通过ROC曲线和Kaplan-Meier生存分析评估血钙水平对SFTS患者临床结局的预测能力。结果:与存活组相比,死亡组患者的APTT、PT、D-D、Cr、BUN、ALT、AST、CK-MB、LDH、钾、CRP、IL-6、IL-8、IL-10水平显著升高(P < 0.05);而PLT、L、M、Fib、GFR、钙和碳酸氢根水平则显著降低(P < 0.05)。年龄(HR = 1.875, 95%CI: 1.120~3.138, P = 0.017)和IL-10 (HR = 1.004, 95%CI: 1.002~1.006, P < 0.001)是患者死亡的独立危险因素;而血钙水平(HR = 0.022, 95%CI: 0.001~0.480, P = 0.015)是独立保护因素。结论:血清钙离子水平对早期评估SFTS患者临床预后具有重要价值,可为病情评估和临床诊疗提供重要参考信息。
Objective: To investigate the value of serum calcium levels in predicting the prognosis of patients with severe fever with thrombocytopenia syndrome (SFTS). Methods: A retrospective study was conducted to collect clinical data from 181 patients diagnosed with Severe Fever with Thrombocytopenia Syndrome (SFTS) and admitted to the First Affiliated Hospital of Anhui Medical University. Patients were classified into two groups based on clinical outcomes: the death group (44 cases) and the survival group (137 cases). Comparative analysis was performed on the age and laboratory markers of these two patient groups. Univariate and multivariate Cox regression analyses were utilized to explore in-dependent risk factors for adverse outcomes, while ROC curve and Kaplan-Meier survival analysis were employed to evaluate the predictive ability of blood calcium levels on clinical outcomes in patients with SFTS. Results: Compared to the survival group, deceased patients showed significantly elevated levels of APTT, PT, D-D, Cr, BUN, ALT, AST, CK-MB, LDH, potassium, CRP, IL-6, IL-8, and IL-10 (P < 0.05). Conversely, PLT, L, M, Fib, GFR, calcium, and bicarbonate levels were significantly decreased (P < 0.05). Furthermore, age (HR = 1.875, 95%CI: 1.120~3.138, P = 0.017) and IL-10 (HR = 1.004, 95%CI: 1.002~1.006, P < 0.001) emerged as independent risk factors for patient mortality, while blood calcium level (HR = 0.022, 95%CI: 0.001~0.480, P = 0.015) was identified as an independent protective factor. Conclusion: Serum calcium levels are crucial for early prognosis evaluation in SFTS patients, offering vital insights for diagnosis and treatment planning.

References

[1]  Tran, X.C., Yun, Y., Van An, L., et al. (2019) Endemic Severe Fever with Thrombocytopenia Syndrome, Vietnam. Emerging Infectious Diseases, 25, 1029-1031.
https://doi.org/10.3201/eid2505.181463
[2]  Yu, X.-J., Liang, M.-F., Zhang, S.-Y., et al. (2011) Fever with Thrombocytopenia Associated with a Novel Bunyavirus in China. The New England Journal of Medicine, 364, 1523-1532.
https://doi.org/10.1056/NEJMoa1010095
[3]  Lin, T.-L., Ou, S.-C., Maeda, K., et al. (2020) The First Discovery of Severe Fever with Thrombocytopenia Syndrome Virus in Taiwan. Emerging Microbes & Infections, 9, 148-151.
https://doi.org/10.1080/22221751.2019.1710436
[4]  雷雯, 赵鑫, 刘建华, 等. 鄂西地区某县一起发热伴血小板减少综合征聚集性疫情调[J]. 中国媒介生物学及控制杂志, 2024, 35(1): 100-103.
[5]  罗银波, 刘力, 黄鑫胜, 等. 2023年湖北省某地一起发热伴血小板减少综合征聚集性疫情调查[J]. 疾病监测, 2024(3): 1-7.
[6]  董棒, 褚雨, 单晨啸, 等. 枣庄市27例发热伴血小板减少综合征患者流行病学及临床特征分析[J]. 中华卫生杀虫药械, 2024, 30(1): 59-61.
[7]  Li, J., Li, S., Yang, L., et al. (2021) Severe Fever with Thrombocytopenia Syndrome Virus: A Highly Lethal Bunyavirus. Critical Reviews in Microbiology, 47, 112-125.
https://doi.org/10.1080/1040841X.2020.1847037
[8]  Casel, M.A., Park, S.J. and Choi, Y.K. (2021) Severe Fever with Thrombocytopenia Syndrome Virus: Emerging Novel Phlebovirus and Their Control Strategy. Experimental & Molecular Medicine, 53, 713-722.
https://doi.org/10.1038/s12276-021-00610-1
[9]  Zhang, X., Liu, Y., Zhao, L., et al. (2013) An Emerging Hemorrhagic Fever in China Caused by a Novel Bunyavirus SFTSV. Science China. Life Sciences, 56, 697-700.
https://doi.org/10.1007/s11427-013-4518-9
[10]  来利娅, 骆欣, 朱炜, 等. 2012-2022年杭州地区发热伴血小板减少综合征患者新布尼亚病毒监测及预后影响因素分析[J]. 中国地方病防治, 2023, 38(6): 497-498.
[11]  Hu, J.-L., Li, Z.-F., Wang, X.-C., et al. (2016) Risk Factors for Bunyavirus-Associated Severe Fever with Thrombocytopenia Syndrome: A Community-Based Case-Control Study. PLOS ONE, 11, e0166611.
https://doi.org/10.1371/journal.pone.0166611
[12]  Gong, L., Zhang, L., Wu, J., et al. (2021) Clinical Progress and Risk Factors for Death from Severe Fever with Thrombocytopenia Syndrome: A Multihospital Retrospective Investigation in Anhui, China. The American Journal of Tropical Medicine and Hygiene, 104, 1425-1431.
https://doi.org/10.4269/ajtmh.20-0270
[13]  Liu, Q., He, B., Huang, S.-Y., et al. (2014) Severe Fever with Thrombocytopenia Syndrome, an Emerging Tick-Borne Zoonosis. The Lancet. Infectious Diseases, 14, 763-772.
https://doi.org/10.1016/S1473-3099(14)70718-2
[14]  Wang, G., Xu, Y.-L., Zhu, Y., et al. (2023) Clinical Efficacy of Low-Dose Glucocorticoid Therapy for Critically Ill Patients with Severe Fever with Thrombocytopenia Syndrome: A Retrospective Cohort Study. International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases, 130, 153-160.
https://doi.org/10.1016/j.ijid.2023.03.015
[15]  Takayama-Ito, M. and Saijo, M. (2020) Antiviral Drugs against Severe Fever with Thrombocytopenia Syndrome Virus Infection. Frontiers in Microbiology, 11, Article No. 150.
https://doi.org/10.3389/fmicb.2020.00150
[16]  Zhang, S.-S., Du, J., Cui, N., et al. (2023) Clinical Efficacy of Immunoglobulin on the Treatment of Severe Fever with Thrombocytopenia Syndrome: A Retrospective Cohort Study. EBioMedicine, 96, Article ID: 104807.
https://doi.org/10.1016/j.ebiom.2023.104807
[17]  Lu, Q.-B., Zhang, S.-Y., Cui, N., et al. (2015) Common Adverse Events Associated with Ribavirin Therapy for Severe Fever with Thrombocytopenia Syndrome. Antiviral Research, 119, 19-22.
https://doi.org/10.1016/j.antiviral.2015.04.006
[18]  Xia, G., Sun, S., Zhou, S., et al. (2023) A New Model for Predicting the Outcome and Effectiveness of Drug Therapy in Patients with Severe Fever with Thrombocytopenia Syndrome: A Multicenter Chinese Study. PLOS Neglected Tropical Diseases, 17, e0011158.
https://doi.org/10.1371/journal.pntd.0011158
[19]  Yuan, Y., Lu, Q.-B., Yao, W.-S., et al. (2021) Clinical Efficacy and Safety Evaluation of Favipiravir in Treating Patients with Severe Fever with Thrombocytopenia Syndrome. EBioMedicine, 72, Article ID: 103591.
https://doi.org/10.1016/j.ebiom.2021.103591
[20]  Xiong, L., Xu, L., Lv, X., et al. (2022) Effects of Corticosteroid Treatment in Patients with Severe Fever with Thrombocytopenia Syndrome: A Single-Center Retrospective Cohort Study. International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases, 122, 1026-1033.
https://doi.org/10.1016/j.ijid.2022.07.001
[21]  陈广, 陈韬, 舒赛男, 等. 重症发热伴血小板减少综合征诊治专家共识[J]. 传染病信息, 2022, 35(5): 385-393.
[22]  Li, X.-K., Dai, K., Yang, Z.-D., et al. (2020) Correlation between Thrombocytopenia and Host Response in Severe Fever with Thrombocytopenia Syndrome. PLOS Neglected Tropical Diseases, 14, e0008801.
https://doi.org/10.1371/journal.pntd.0008801
[23]  Dai, Z.-N., Peng, X.-F., Li, J.-C., et al. (2022) Effect of Genomic Variations in Severe Fever with Thrombocytopenia Syndrome Virus on the Disease Lethality. Emerging Microbes & Infections, 11, 1672-1682.
https://doi.org/10.1080/22221751.2022.2081617
[24]  Ge, H.-H., Wang, G., Guo, P.-J., et al. (2022) Coinfections in Hospitalized Patients with Severe Fever with Thrombocytopenia Syndrome: A Retrospective Study. Journal of Medical Virology, 94, 5933-5942.
https://doi.org/10.1002/jmv.28093
[25]  李春晶, 刘庆华, 全传松, 等. 重症发热伴血小板减少综合征临床特征研究[J]. 医学信息, 2023, 36(6): 172-175.
[26]  Westover, J.B., Hickerson, B.T., Van Wettere, A.J., et al. (2019) Vascular Leak and Hypercytokinemia Associated with Severe Fever with Thrombocytopenia Syndrome Virus Infection in Mice. Pathogens (Basel, Switzerland), 8, Article No. 158.
https://doi.org/10.3390/pathogens8040158
[27]  Jin, C., Liang, M., Ning, J., et al. (2012) Pathogenesis of Emerging Severe Fever with Thrombocytopenia Syndrome Virus in C57/BL6 Mouse Model. Proceedings of the National Academy of Sciences of the United States of America, 109, 10053-10058.
https://doi.org/10.1073/pnas.1120246109
[28]  颜月, 刘宇飞. APTT对发热伴血小板减少综合征预后的评估价值[J]. 大连医科大学学报, 2023, 45(6): 503-508.
[29]  王博昊, 易志杰, 黄雨馨, 等. 发热伴血小板减少综合征患者病情严重程度关联因素分析[J]. 郑州大学学报(医学版), 2021, 56(5): 640-644.
[30]  Li, H., Zhang, L.-K., Li, S.-F., et al. (2019) Calcium Channel Blockers Reduce Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Related Fatality. Cell Research, 29, 739-753.
https://doi.org/10.1038/s41422-019-0214-z
[31]  赵国敏, 边伟帅, 甄洁, 等. 血清钾、钙、镁对评估脓毒症患者预后的临床价值[J]. 中国老年学杂志, 2024, 44(5): 1075-1079.
[32]  Hoffmann, H.H., Schneider, W.M., Blomen, V.A., et al. (2017) Diverse Viruses Require the Calcium Transporter SPCA1 for Maturation and Spread. Cell Host & Microbe, 22, 460-470.e5.
https://doi.org/10.1016/j.chom.2017.09.002
[33]  Li, J.-C., Zhao, J., Li, H., et al. (2022) Epidemiology, Clinical Characteristics, and Treatment of Severe Fever with Thrombocytopenia Syndrome. Infectious Medicine, 1, 40-49.
https://doi.org/10.1016/j.imj.2021.10.001
[34]  Wang, M., Tan, W., Li, J., et al. (2022) The Endless Wars: Severe Fever with Thrombocytopenia Syndrome Virus, Host Immune and Genetic Factors. Frontiers in Cellular and Infection Microbiology, 12, Article ID: 808098.
https://doi.org/10.3389/fcimb.2022.808098

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133